Is OCS or CRBU more profitable?

Caribou Biosciences has a net margin of -1,189.14% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Caribou Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -8,460.67% -56.78% -45.62% Caribou Biosciences -1,189.14% -84.17% -60.51%

Does the media favor OCS or CRBU?

In the previous week, Oculis had 1 more articles in the media than Caribou Biosciences. MarketBeat recorded 3 mentions for Oculis and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.93 beat Oculis' score of 0.22 indicating that Caribou Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caribou Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRBU or ACRS?

In the previous week, Caribou Biosciences and Caribou Biosciences both had 2 articles in the media. Caribou Biosciences' average media sentiment score of 0.93 equaled Aclaris Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caribou Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRBU or CADL?

In the previous week, Candel Therapeutics had 6 more articles in the media than Caribou Biosciences. MarketBeat recorded 8 mentions for Candel Therapeutics and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.93 beat Candel Therapeutics' score of 0.38 indicating that Caribou Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caribou Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer DNA or CRBU?

In the previous week, Caribou Biosciences had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 2 mentions for Caribou Biosciences and 1 mentions for Ginkgo Bioworks. Caribou Biosciences' average media sentiment score of 0.93 beat Ginkgo Bioworks' score of 0.00 indicating that Caribou Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caribou Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Caribou Biosciences (CRBU) Competitors

$1.76 -0.01 (-0.56%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$1.76 +0.00 (+0.28%)

As of 06/30/2026 07:54 PM Eastern

Compare

CRBU vs. OCS, ACRS, CADL, GYRE, and DNA

Should you buy Caribou Biosciences stock or one of its competitors? MarketBeat compares Caribou Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Caribou Biosciences include Oculis (OCS), Aclaris Therapeutics (ACRS), Candel Therapeutics (CADL), Gyre Therapeutics (GYRE), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry.

How does Caribou Biosciences compare to Oculis?

Oculis (NASDAQ:OCS) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

In the previous week, Oculis had 1 more articles in the media than Caribou Biosciences. MarketBeat recorded 3 mentions for Oculis and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.93 beat Oculis' score of 0.22 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caribou Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oculis has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.33, suggesting that its share price is 133% more volatile than the broader market.

Caribou Biosciences has a net margin of -1,189.14% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%

Oculis currently has a consensus target price of $38.33, suggesting a potential upside of 176.38%. Caribou Biosciences has a consensus target price of $8.67, suggesting a potential upside of 392.42%. Given Caribou Biosciences' higher probable upside, analysts plainly believe Caribou Biosciences is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Oculis has higher earnings, but lower revenue than Caribou Biosciences. Oculis is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	N/A	N/A	-$119.44M	-$2.13	N/A
Caribou Biosciences	$11.16M	15.64	-$148.12M	-$1.42	N/A

22.3% of Oculis shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Caribou Biosciences beats Oculis on 10 of the 16 factors compared between the two stocks.

How does Caribou Biosciences compare to Aclaris Therapeutics?

Caribou Biosciences (NASDAQ:CRBU) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Aclaris Therapeutics has lower revenue, but higher earnings than Caribou Biosciences. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16M	15.64	-$148.12M	-$1.42	N/A
Aclaris Therapeutics	$7.83M	94.36	-$64.92M	-$0.56	N/A

In the previous week, Caribou Biosciences and Caribou Biosciences both had 2 articles in the media. Caribou Biosciences' average media sentiment score of 0.93 equaled Aclaris Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caribou Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Caribou Biosciences has a beta of 2.33, meaning that its share price is 133% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Aclaris Therapeutics has a net margin of -832.58% compared to Caribou Biosciences' net margin of -1,189.14%. Aclaris Therapeutics' return on equity of -55.89% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

Caribou Biosciences presently has a consensus price target of $8.67, suggesting a potential upside of 392.42%. Aclaris Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 117.39%. Given Caribou Biosciences' higher possible upside, equities research analysts clearly believe Caribou Biosciences is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Summary

Aclaris Therapeutics beats Caribou Biosciences on 10 of the 15 factors compared between the two stocks.

How does Caribou Biosciences compare to Candel Therapeutics?

Caribou Biosciences (NASDAQ:CRBU) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Candel Therapeutics has lower revenue, but higher earnings than Caribou Biosciences. Candel Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16M	15.64	-$148.12M	-$1.42	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Caribou Biosciences has a beta of 2.33, indicating that its stock price is 133% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.49, indicating that its stock price is 149% less volatile than the broader market.

In the previous week, Candel Therapeutics had 6 more articles in the media than Caribou Biosciences. MarketBeat recorded 8 mentions for Candel Therapeutics and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.93 beat Candel Therapeutics' score of 0.38 indicating that Caribou Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caribou Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Caribou Biosciences presently has a consensus price target of $8.67, indicating a potential upside of 392.42%. Candel Therapeutics has a consensus price target of $18.00, indicating a potential upside of 74.76%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Caribou Biosciences is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Candel Therapeutics has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,189.14%. Candel Therapeutics' return on equity of -60.42% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%
Candel Therapeutics	N/A	-60.42%	-41.33%

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Caribou Biosciences and Candel Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Caribou Biosciences compare to Gyre Therapeutics?

Caribou Biosciences (NASDAQ:CRBU) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

In the previous week, Caribou Biosciences had 1 more articles in the media than Gyre Therapeutics. MarketBeat recorded 2 mentions for Caribou Biosciences and 1 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.87 beat Caribou Biosciences' score of 0.93 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Caribou Biosciences	Positive
Gyre Therapeutics	Very Positive

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Caribou Biosciences currently has a consensus target price of $8.67, suggesting a potential upside of 392.42%. Gyre Therapeutics has a consensus target price of $17.00, suggesting a potential upside of 157.97%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Caribou Biosciences is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Gyre Therapeutics has a net margin of -5.44% compared to Caribou Biosciences' net margin of -1,189.14%. Gyre Therapeutics' return on equity of 3.13% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%
Gyre Therapeutics	-5.44%	3.13%	2.67%

Caribou Biosciences has a beta of 2.33, meaning that its share price is 133% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market.

Gyre Therapeutics has higher revenue and earnings than Caribou Biosciences. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16M	15.64	-$148.12M	-$1.42	N/A
Gyre Therapeutics	$116.59M	6.30	$5.03M	-$0.09	N/A

Summary

Caribou Biosciences and Gyre Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Caribou Biosciences compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Ginkgo Bioworks has a net margin of -215.41% compared to Caribou Biosciences' net margin of -1,189.14%. Ginkgo Bioworks' return on equity of -56.08% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%

In the previous week, Caribou Biosciences had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 2 mentions for Caribou Biosciences and 1 mentions for Ginkgo Bioworks. Caribou Biosciences' average media sentiment score of 0.93 beat Ginkgo Bioworks' score of 0.00 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caribou Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ginkgo Bioworks presently has a consensus target price of $8.50, suggesting a potential downside of 14.46%. Caribou Biosciences has a consensus target price of $8.67, suggesting a potential upside of 392.42%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Caribou Biosciences is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Ginkgo Bioworks has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.33, indicating that its stock price is 133% more volatile than the broader market.

78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Caribou Biosciences has lower revenue, but higher earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.81	-$312.76M	-$5.36	N/A
Caribou Biosciences	$11.16M	15.64	-$148.12M	-$1.42	N/A

Summary

Caribou Biosciences beats Ginkgo Bioworks on 11 of the 17 factors compared between the two stocks.

Get Caribou Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRBU vs. The Competition

Export

Metric	Caribou Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$175.55M	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-1.24	20.90	27.51	24.87
Price / Sales	15.64	341.80	540.69	102.84
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	1.34	8.75	11.01	6.54
Net Income	-$148.12M	$23.81M	$3.57B	$336.70M
7 Day Performance	6.02%	3.60%	2.31%	2.88%
1 Month Performance	-27.57%	3.72%	1.38%	0.64%
1 Year Performance	40.80%	68.80%	36.70%	31.34%

Caribou Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRBU Caribou Biosciences	2.202 of 5 stars	$1.76 -0.6%	$8.67 +392.4%	+39.7%	$175.55M	$11.16M	N/A	100
OCS Oculis	3.2682 of 5 stars	$11.67 +4.0%	$38.33 +228.5%	-28.5%	$650.59M	$1.45M	N/A	2	Short Interest Increase
ACRS Aclaris Therapeutics	3.1562 of 5 stars	$4.84 +7.6%	$11.50 +137.6%	+272.5%	$628.49M	$8.37M	N/A	100
CADL Candel Therapeutics	2.7921 of 5 stars	$9.15 +10.1%	$18.00 +96.7%	+103.6%	$608.88M	N/A	N/A	60	News Coverage
GYRE Gyre Therapeutics	2.1512 of 5 stars	$6.13 -1.9%	$17.00 +177.3%	-10.3%	$606.43M	$117.05M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRBU) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Caribou Biosciences (CRBU) Competitors

CRBU vs. OCS, ACRS, CADL, GYRE, and DNA

How does Caribou Biosciences compare to Oculis?

Summary

How does Caribou Biosciences compare to Aclaris Therapeutics?

Summary

How does Caribou Biosciences compare to Candel Therapeutics?

Summary

How does Caribou Biosciences compare to Gyre Therapeutics?

Summary

How does Caribou Biosciences compare to Ginkgo Bioworks?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBU vs. The Competition

Caribou Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Caribou Biosciences (CRBU) Competitors

CRBU vs. OCS, ACRS, CADL, GYRE, and DNA

How does Caribou Biosciences compare to Oculis?

Does the media favor OCS or CRBU?

Which has more volatility and risk, OCS or CRBU?

Is OCS or CRBU more profitable?

Do analysts prefer OCS or CRBU?

Which has preferable earnings and valuation, OCS or CRBU?

Do insiders and institutionals have more ownership in OCS or CRBU?

Summary

How does Caribou Biosciences compare to Aclaris Therapeutics?

Which has preferable valuation & earnings, CRBU or ACRS?

Does the media prefer CRBU or ACRS?

Do insiders & institutionals hold more shares of CRBU or ACRS?

Which has more volatility & risk, CRBU or ACRS?

Is CRBU or ACRS more profitable?

Do analysts rate CRBU or ACRS?

Summary

How does Caribou Biosciences compare to Candel Therapeutics?

Which has stronger earnings and valuation, CRBU or CADL?

Which has more volatility & risk, CRBU or CADL?

Does the media prefer CRBU or CADL?

Do analysts recommend CRBU or CADL?

Is CRBU or CADL more profitable?

Do institutionals & insiders believe in CRBU or CADL?

Summary

How does Caribou Biosciences compare to Gyre Therapeutics?

Does the media refer more to CRBU or GYRE?

Do institutionals & insiders have more ownership in CRBU or GYRE?

Do analysts prefer CRBU or GYRE?

Is CRBU or GYRE more profitable?

Which has more volatility & risk, CRBU or GYRE?

Which has better valuation and earnings, CRBU or GYRE?

Summary

How does Caribou Biosciences compare to Ginkgo Bioworks?

Is DNA or CRBU more profitable?

Does the media prefer DNA or CRBU?

Do analysts rate DNA or CRBU?

Which has more volatility & risk, DNA or CRBU?

Do insiders & institutionals hold more shares of DNA or CRBU?

Which has stronger valuation & earnings, DNA or CRBU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBU vs. The Competition

Caribou Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools